Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of MK-2870 alone or with pembrolizumab versus physician's choice chemotherapy in advanced HR-positive/HER2-negative breast cancer
MOH_2024-03-17_013307Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in breast cancer (3 arms), sponsored by Merck & Co. Started Mar 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-03-17_013307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-17_013307.